$NCRA
NOCERA, INC.

2024 Q1 Form 10-Q Financial Statement

#000168316824003458 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $4.900M
YoY Change 91452.32%
Cost Of Revenue $4.816M
YoY Change 27.77%
Gross Profit $83.96K
YoY Change 22.29%
Gross Profit Margin 1.71%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $22.56K
YoY Change -49.56%
% of Gross Profit 26.87%
Operating Expenses $575.6K
YoY Change -45.66%
Operating Profit -$491.7K
YoY Change -50.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.270K
YoY Change -80.27%
Pretax Income -$493.9K
YoY Change -50.72%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$486.4K
YoY Change -50.75%
Net Earnings / Revenue -9.93%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04
COMMON SHARES
Basic Shares Outstanding 11.96M shares 10.04M shares
Diluted Shares Outstanding 11.96M shares

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $961.8K $1.230M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $86.45K $88.43K
Prepaid Expenses
Receivables $172.3K $173.4K
Other Receivables
Total Short-Term Assets $1.940M $1.712M
YoY Change -1.48% -47.1%
LONG-TERM ASSETS
Property, Plant & Equipment $1.538M $1.548M
YoY Change -8.82% 83.26%
Goodwill $3.007M $1.655M
YoY Change -23.01% -57.62%
Intangibles $110.1K $114.1K
YoY Change -12.9% -12.5%
Long-Term Investments
YoY Change
Other Assets $378.2K $4.730K
YoY Change 7827.9%
Total Long-Term Assets $5.033M $3.322M
YoY Change -12.42% -32.26%
TOTAL ASSETS
Total Short-Term Assets $1.940M $1.712M
Total Long-Term Assets $5.033M $3.322M
Total Assets $6.972M $5.034M
YoY Change -9.62% -38.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $368.5K $0.00
YoY Change 14747.1% -100.0%
Accrued Expenses
YoY Change
Deferred Revenue $0.00
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.232M $1.770M
YoY Change 50.12% 16.34%
LONG-TERM LIABILITIES
Long-Term Debt $36.09K $0.00
YoY Change -90.99% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $36.09K $0.00
YoY Change -90.99% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.232M $1.770M
Total Long-Term Liabilities $36.09K $0.00
Total Liabilities $2.268M $1.770M
YoY Change 20.18% -9.59%
SHAREHOLDERS EQUITY
Retained Earnings -$19.54M -$19.05M
YoY Change 24.18% 29.2%
Common Stock $12.96K $11.16K
YoY Change 33.67% 20.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.631M $3.179M
YoY Change
Total Liabilities & Shareholders Equity $6.972M $5.034M
YoY Change -9.62% -38.16%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$486.4K
YoY Change -50.75%
Depreciation, Depletion And Amortization $22.56K
YoY Change -49.56%
Cash From Operating Activities -$461.0K
YoY Change 26.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $201.9K
YoY Change -119.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$60.68K
YoY Change 47.5%
NET CHANGE
Cash From Operating Activities -$461.0K
Cash From Investing Activities $201.9K
Cash From Financing Activities -$60.68K
Net Change In Cash -$267.8K
YoY Change -81.47%
FREE CASH FLOW
Cash From Operating Activities -$461.0K
Capital Expenditures $0.00
Free Cash Flow -$461.0K
YoY Change -62.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-41434
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NOCERA, INC.
CY2024Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Xizhi Dist.
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New Taipei City
CY2024Q1 dei Entity Address Country
EntityAddressCountry
TW
CY2024Q1 dei City Area Code
CityAreaCode
886
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
2-2690-7086
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
NCRA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
0 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
0 usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
16-1626611
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3F (Building B), No. 185
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 NCRA Advance To Suppliers
AdvanceToSuppliers
1732 usd
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 usd
CY2023Q4 NCRA Advance Receipts
AdvanceReceipts
0 usd
CY2023Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1179768 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23924311 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
21931112 usd
CY2024Q1 NCRA Statutory And Other Reserves
StatutoryAndOtherReserves
191219 usd
CY2023Q4 NCRA Statutory And Other Reserves
StatutoryAndOtherReserves
191219 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19539492 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19053072 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
41599 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
98906 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4630674 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3179402 usd
CY2024Q1 us-gaap Minority Interest
MinorityInterest
73537 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
84325 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4704211 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3263727 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6972418 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5034043 usd
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4899880 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3837863 usd
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4815919 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3769207 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
83961 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
68656 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
575611 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1059337 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
575611 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1059337 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-491650 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-990681 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2270 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11508 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-493920 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1002189 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-493920 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1002189 usd
CY2024Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7500 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14541 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-486420 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-987648 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-493920 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1002189 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
57307 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-23288 usd
CY2024Q1 NCRA Total Comprehensive Loss
TotalComprehensiveLoss
-436613 usd
CY2023Q1 NCRA Total Comprehensive Loss
TotalComprehensiveLoss
-1025477 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-5622 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-14880 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-430991 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1010597 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.0407
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1063
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.0407
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1063
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11956987 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9293587 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11956987 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9293587 shares
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-493920 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1002189 usd
CY2024Q1 us-gaap Depreciation
Depreciation
22559 usd
CY2023Q1 us-gaap Depreciation
Depreciation
44728 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
922 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
231 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4076 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4076 usd
CY2024Q1 NCRA Gain On Fair Value Change Of Financial Assets Held For Trading
GainOnFairValueChangeOfFinancialAssetsHeldForTrading
2409 usd
CY2023Q1 NCRA Gain On Fair Value Change Of Financial Assets Held For Trading
GainOnFairValueChangeOfFinancialAssetsHeldForTrading
-0 usd
CY2024Q1 NCRA Consultancy Services Settled By Equities
ConsultancyServicesSettledByEquities
0 usd
CY2023Q1 NCRA Consultancy Services Settled By Equities
ConsultancyServicesSettledByEquities
521100 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14999 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
103155 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4170 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5098 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-0 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1343 usd
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
117346 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-82 usd
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4865 usd
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
0 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-149 usd
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
116071 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4368 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
30 usd
CY2024Q1 NCRA Increase Decrease In Advance Receipt
IncreaseDecreaseInAdvanceReceipt
-0 usd
CY2023Q1 NCRA Increase Decrease In Advance Receipt
IncreaseDecreaseInAdvanceReceipt
32180 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-460993 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-364370 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
857870 usd
CY2024Q1 NCRA Purchase Of Financial Assets At Fvtpl
PurchaseOfFinancialAssetsAtFvtpl
-0 usd
CY2023Q1 NCRA Purchase Of Financial Assets At Fvtpl
PurchaseOfFinancialAssetsAtFvtpl
200951 usd
CY2024Q1 NCRA Net Cash Inflow From Acquisition Of Subsidiary
NetCashInflowFromAcquisitionOfSubsidiary
201863 usd
CY2023Q1 NCRA Net Cash Inflow From Acquisition Of Subsidiary
NetCashInflowFromAcquisitionOfSubsidiary
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
201863 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1058821 usd
CY2024Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
60678 usd
CY2023Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
41137 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-60678 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-41137 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52005 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18758 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-267803 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1445570 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1229580 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2906074 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
961777 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1460504 usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6182247 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
23288 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
103155 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
521100 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1002189 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5827601 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3263727 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-60595 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1980000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
14999 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-493920 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4704211 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zP7SRwiGskkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_z96NLRn0EN3i">Concentrations of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of accounts receivable. The Company conducts credit evaluations of its customers and suppliers, and generally does not require collateral or other security from them. The Company evaluates its collection experience and long outstanding balances to determine the need for an allowance for doubtful accounts. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were four customers who represent <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FourCustomersMember_zYMAYHIIJWk3" title="Concentration risk">95</span>% of the Company’s total revenue for the three months ended March 31, 2023. There were five customers who represent <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FiveCustomersMember_zTsTieebFbbf" title="Concentration risk">93</span>% of the Company’s total revenue for the three months ended March 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of single customers who represent 10% or more of the Company’s total accounts receivable, net:</p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_z0hu5KJyCs22" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICY (Details - Concentrations)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8B5_z5lyajc9gl4i" style="display: none">Schedule of concentrations of credit risk</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="padding-bottom: 1pt; text-align: left"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Audited)</b></span></td><td style="padding-bottom: 1pt; text-align: left"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Percentage of the Company’s accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeIZJn24a2H3" title="Concentration percentage">59.13</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQTFb6n21bW7" title="Concentration percentage">60.11</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRTNVrd5atW5" title="Concentration percentage">10.96</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoqMCmFIA5N2" title="Concentration percentage">21.99</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcIYi3VzoQ64" title="Concentration percentage">29.41</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp0_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM9CK3pMbuq8" title="Concentration percentage">–</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Customer D</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp0_c20240101__20240331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSy5Wk7Lumnf" title="Concentration percentage">–</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGixipetom5b" title="Concentration percentage">16.10</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__srt--MajorCustomersAxis__custom--AllCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWspr7w7du06" title="Concentration percentage">99.50</span>%</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__srt--MajorCustomersAxis__custom--AllCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zanuWGjvwLn9" title="Concentration percentage">98.19</span>%</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q1 us-gaap Accounts Receivable Gross
AccountsReceivableGross
172310 usd
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
173395 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
172310 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
173395 usd
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2024Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
86445 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
88432 usd
CY2024Q1 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
0 usd
CY2023Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
0 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
86445 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
88432 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
506257 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
10365 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
506257 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10365 usd
CY2024Q1 us-gaap Land
Land
877870 usd
CY2023Q4 us-gaap Land
Land
877870 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
268780 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
235499 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1537692 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1547801 usd
CY2024Q1 us-gaap Depreciation
Depreciation
22559 usd
CY2023Q1 us-gaap Depreciation
Depreciation
44728 usd
CY2024Q1 NCRA Financial Assets At Fair Value Through Profit Or Loss Funds
FinancialAssetsAtFairValueThroughProfitOrLossFunds
211106 usd
CY2023Q4 NCRA Financial Assets At Fair Value Through Profit Or Loss Funds
FinancialAssetsAtFairValueThroughProfitOrLossFunds
208697 usd
CY2024Q1 NCRA Financial Assets At Fair Value Through Profit Or Loss
FinancialAssetsAtFairValueThroughProfitOrLoss
211106 usd
CY2023Q4 NCRA Financial Assets At Fair Value Through Profit Or Loss
FinancialAssetsAtFairValueThroughProfitOrLoss
208697 usd
CY2024Q1 NCRA Financial Assets Measured At Fair Value Through Profit Or Loss Non Current
FinancialAssetsMeasuredAtFairValueThroughProfitOrLossNonCurrent
211106 usd
CY2023Q4 NCRA Financial Assets Measured At Fair Value Through Profit Or Loss Non Current
FinancialAssetsMeasuredAtFairValueThroughProfitOrLossNonCurrent
208697 usd
CY2024Q1 us-gaap Derivative Assets
DerivativeAssets
211106 usd
CY2023Q4 us-gaap Derivative Assets
DerivativeAssets
208697 usd
CY2024Q1 us-gaap Gain Loss On Disposition Of Other Financial Assets
GainLossOnDispositionOfOtherFinancialAssets
2409 usd
CY2024Q1 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
0 usd
CY2024Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
2250553 usd
CY2023Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
2250553 usd
CY2024Q1 us-gaap Goodwill
Goodwill
3006885 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1655182 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
135325 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
135325 usd
CY2024Q1 NCRA Finite Lived Intangible Assets Acquisitions
FiniteLivedIntangibleAssetsAcquisitions
0 usd
CY2023Q4 NCRA Finite Lived Intangible Assets Acquisitions
FiniteLivedIntangibleAssetsAcquisitions
0 usd
CY2024Q1 NCRA Finite Lived Intangible Assets Translation Adjustments
FiniteLivedIntangibleAssetsTranslationAdjustments
0 usd
CY2023Q4 NCRA Finite Lived Intangible Assets Translation Adjustments
FiniteLivedIntangibleAssetsTranslationAdjustments
0 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25272 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21196 usd
CY2024Q1 NCRA Accumulated Impairment Of Intangible Assets Excluding Goodwill
AccumulatedImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2023Q4 NCRA Accumulated Impairment Of Intangible Assets Excluding Goodwill
AccumulatedImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
110053 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
114129 usd
CY2024Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
426322 usd
CY2023Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
487800 usd
CY2024Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
426322 usd
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
487800 usd
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
2:3 reverse stock split
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1179768 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1179768 usd
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
0 usd
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
0 usd
CY2024Q1 NCRA Warrants Redeemed
WarrantsRedeemed
0 usd
CY2023 NCRA Warrants Redeemed
WarrantsRedeemed
0 usd
CY2024Q1 NCRA Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings1
0 usd
CY2023 NCRA Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings1
0 usd
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1179768 usd
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1179768 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
18791 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
9886 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
18791 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
9886 usd
CY2024Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
0 usd
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
0 usd
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
823 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
842 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32735 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33251 usd
CY2024Q1 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
33558 usd
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
34093 usd
CY2024Q1 NCRA Value Added Tax Rate
ValueAddedTaxRate
0.16 pure
CY2023Q4 NCRA Value Added Tax Rate
ValueAddedTaxRate
0.13 pure
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Gilti Amount
EffectiveIncomeTaxRateReconciliationGiltiAmount
152829 usd
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings
EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
0.2000 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings
EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
0.2000 pure
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0315 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0154 pure
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.0441 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.1029 pure
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0 pure
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0015 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0005 pure
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0 pure
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1229 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0811 pure
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2024Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23391 usd
CY2024Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
0 usd
CY2024Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23391 usd
CY2024Q1 NCRA Reversal Of Deferred Tax Assets
ReversalOfDeferredTaxAssets
0 usd
CY2023Q4 NCRA Reversal Of Deferred Tax Assets
ReversalOfDeferredTaxAssets
-23391 usd
CY2024Q1 NCRA Deferred Tax Assets Valuation Allowance Currents
DeferredTaxAssetsValuationAllowanceCurrents
0 usd
CY2023Q4 NCRA Deferred Tax Assets Valuation Allowance Currents
DeferredTaxAssetsValuationAllowanceCurrents
0 usd
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q1 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0 usd
CY2024Q1 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
95844 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
95844 usd
CY2024Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0 usd
CY2024Q1 NCRA Valuation Allowance Deferred Tax Asset Change In Amount1
ValuationAllowanceDeferredTaxAssetChangeInAmount1
0 usd
CY2023 NCRA Valuation Allowance Deferred Tax Asset Change In Amount1
ValuationAllowanceDeferredTaxAssetChangeInAmount1
0 usd
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
95844 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
95844 usd
CY2024Q1 NCRA Due From A Related Party
DueFromARelatedParty
0 usd
CY2023Q4 NCRA Due From A Related Party
DueFromARelatedParty
5352 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
2:3 reverse stock split
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12956987 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11156987 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0116 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0116 pure
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M21D
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M21D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4815 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4815 pure
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
103155 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
163621 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 usd
CY2021Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.001
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.50
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
2:3 reverse stock split
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-486420 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-987648 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11956987 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9293587 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11956987 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9293587 shares
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0407
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.1063
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0407
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.1063
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-003458-index-headers.html Edgar Link pending
0001683168-24-003458-index.html Edgar Link pending
0001683168-24-003458.txt Edgar Link pending
0001683168-24-003458-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ncra-20240331.xsd Edgar Link pending
nocera_ex3101.htm Edgar Link pending
nocera_ex3102.htm Edgar Link pending
nocera_ex3201.htm Edgar Link pending
nocera_ex3202.htm Edgar Link pending
nocera_i10q-033124.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ncra-20240331_def.xml Edgar Link unprocessable
nocera_i10q-033124_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ncra-20240331_cal.xml Edgar Link unprocessable
ncra-20240331_pre.xml Edgar Link unprocessable
ncra-20240331_lab.xml Edgar Link unprocessable